Abstract
An analysis of the long-term results of treatment of 3,681 patients with small cell lung cancer (SCLC) is presented. The data were obtained from major centres in the UK who were conducting treatment trials during the period 1978-1986 and for whom complete computer records and follow-up were available. A total of 217 (5.9%) survived 2 years or more. Two year survival for patients presenting with limited disease (LD) was 8.5% and for extensive disease (ED) 2.2%. Death from SCLC continued until 7 years after diagnosis but not thereafter. At this point overall survival was 3% (3.6% LD, 1.1% ED). Survival after 2 years was not affected by initial disease extent, sex, thoracic radiotherapy or prophylactic cranial irradiation. Death from causes other than SCLC continued throughout the period of observation. Vascular disease, respiratory failure and second tumours were the main other causes of death. The better survival in younger patients was mainly attributable to few deaths from these other causes. These results indicate that only a small proportion of patients with SCLC are cured by current treatment. Although shorter term improvement in survival has been obtained with current treatment, the poor overall long-term results support studies exploring new approaches to cure and to palliation.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Consortia
Rights and permissions
About this article
Cite this article
Souhami, R., Law, K. & A report to the Lung Cancer Subcommittee of the United Kingdom Coordinating Committee for Cancer Research. Longevity in small cell lung cancer. Br J Cancer 61, 584–589 (1990). https://doi.org/10.1038/bjc.1990.131
Issue Date:
DOI: https://doi.org/10.1038/bjc.1990.131
This article is cited by
-
Diagnostik und Therapie des kleinzelligen Lungenkarzinoms
InFo Hämatologie + Onkologie (2022)
-
Differenzialtherapie des fortgeschrittenen metastasierten kleinzelligen Lungenkarzinoms
Der Onkologe (2017)
-
Survival from lung cancer in England and Wales up to 2001
British Journal of Cancer (2008)
-
Identical chemotherapy schedules given on and off trial protocol in small cell lung cancer response and survival results
British Journal of Cancer (2002)